Drugs / sapablursen
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03165864 | May 2017 → Sep 2018 | thalassemia | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT05143957 | Dec 2021 → Jun 2025 | acquired polycythemia vera | Ionis Pharmaceuticals, Inc. | Completed | Met primary |
| Phase 2 | NCT04059406 | Sep 2020 → Mar 2023 | beta-thalassemia intermedia | Ionis Pharmaceuticals, Inc. | Terminated | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT07429266 | May 2026 → Sep 2028 expected | acquired polycythemia vera | Ono Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-12-08 | Ono Pharmaceutical Co., Ltd. | Results Ono Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting ono-pharma.com ↗
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin |
| 2025-12-06 | Deciphera Pharmaceuticals, LLC | Results Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting deciphera.com ↗
The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. |
All press releases naming this drug 6 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sapablursen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07429266 ↗ |
| Known as | IONIS TMPRSS6-Lrx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03165864 ↗ |
| Known as | ISIS 702843 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650478 ↗ |
| Action | Inhibit | “reduces the production of transmembrane protease serine 6 (TMPRSS6)” PMID 42241700 ↗ Jun 2026 |
| Modality | Antisense oligonucleotide | “Sapablursen is an antisense oligonucleotide (ASO)” PMID 42241700 ↗ Jun 2026 |
| Route | Subcutaneous | “IONIS TMPRSS6-Lrx administered subcutaneously” NCT03165864 ↗ |
| Target | TMPRSS6 | “reduces the production of transmembrane protease serine 6 (TMPRSS6)” PMID 42241700 ↗ Jun 2026 |